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Abstract
Purpose This Phase I study assessed whether food
inﬂuences the rate and extent of selumetinib absorption in
patients with advanced solid malignancies and determined
the safety, tolerability, and pharmacokinetic (PK) proﬁle of
selumetinib and its active metabolite N-desmethyl-selu-
metinib in fed and fasted states.
Methods A single dose of 75 mg selumetinib was to be
takenwithfoodonDay1followedbyasingledoseof75 mg
afterfastingforatleast10 honDay8,orviceversa,followed
by twice daily dosing of 75 mg selumetinib from Day 10.
Plasma concentrations and PK parameters were determined
on Days 1 and 8. Patients could continue to receive selu-
metinib for as long as they beneﬁtted from treatment.
Results In total, 31 patients were randomized to receive
selumetinib; 15 to fed/fasted sequence and 16 to fasted/fed
sequence. Comprehensive PK sampling was performed on
11and10patients,respectively.Thegeometricleast-squares
means of Cmax and AUC for selumetinib were reduced by
62%(ratio0.3890%CI0.29,0.50)and19%(ratio0.8190%
CI0.74,0.88),respectively,underfedcomparedwithfasting
conditions.The rate ofabsorption (tmax)ofselumetinib(fed)
was delayed by approximately 2.5 h (median). The food
effect was also observed for the active metabolite N-desm-
ethyl-selumetinib. Selumetinib was well tolerated.
Conclusions The presence of food decreased the extent of
absorption of selumetinib. It is recommended that for fur-
ther clinical studies, selumetinib be taken on an empty
stomach. Selumetinib demonstrated an acceptable safety
proﬁle in the advanced cancer population.
Keywords MEK 1/2 inhibitor  Selumetinib  Phase I 
Food effect
Introduction
Human cancers often arise as a result of mutations within
components of cellular signaling pathways that coordinate
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mitogen-activated protein kinase (MEK)/extracellular sig-
nal-regulated kinase (ERK) pathway (Ras-Raf-MEK-ERK
pathway) is an intracellular key signaling pathway that
transmits mitogenic stimuli from the extracellular environ-
ment to the nucleus of the cell by multiple phosphorylation
steps [1]. The cascade can be schematically divided into
membranous and cytoplasmic phases. When growth factors
bindto,andactivatetransmembranereceptorslocatedonthe
cell surface, the level of guanosine triphosphate-bound
formsofRasincreasesinthecell[2,3].UponRasactivation,
Raf kinases are recruited to the plasma membrane and
become activated. This process results in sequential phos-
phorylation and activation of several protein kinases, col-
lectively known as the mitogen-activated protein kinase
(MAPK) signaling cascade. In the MAPK cascade, Raf
phosphorylates and activates MEK, which in turn phos-
phorylates and activates ERK. Activated ERK dissociates
fromtheRas/Raf/MEK/ERKcomplexandcantranslocateto
the nucleus to phosphorylate and activate numerous differ-
ent transcription factors [3–5]. MEK is the only enzyme
known to activate ERK and being located downstream of
Ras, and Raf has therefore been identiﬁed as an attractive
therapeutic target within this central cascade. Inhibition of
MEK activity is anticipated to inhibit tumor proliferation,
differentiation, and survival. Given the widespread distri-
bution of constitutive ERK activation, a MEK inhibitor
could beforeseen to have a broad spectrum of clinical utility
in both solid tumors and hematological malignancies.
Selumetinib (C17H15BrClFN4O3; AZD6244 and ARRY-
142886) is a potent, selective, non-ATP competitive
inhibitor of MEK with an IC50 of 14 nmol/L against puri-
ﬁed MEK1 [6–8]. In contrast to its activity against MEK
1/2, selumetinib did not show signiﬁcant activity against
various other kinases, enzymes, receptors, ion channels, and
transporters. Selumetinib monotherapy has been clinically
evaluated in a variety of cancers including melanoma,
pancreatic, biliary tract, colorectal, and lung [9–13].
The initial formulation of selumetinib taken into Phase I
was an extemporaneous preparation of an oral suspension
of selumetinib, as the free base in an aqueous solution of
sulphobutylether b-cyclodextrin (Captisol
), also referred
to as selumetinib free base suspension or selumetinib ‘‘mix
and drink formulation’’ [14]. Preclinical pharmacological
studies revealed that this formulation showed good oral
bioavailability at low doses, but there was dose-limited
absorption with increasing dose (i.e. less than proportional
increase), likely reﬂecting the low aqueous solubility of the
free base. Selumetinib free base has a moderate perme-
ability across Caco-2 cells (an in vitro model of the human
small intestinal mucosa used to predict in vivo drug
absorption)andexhibitspHdependentsolubility(274 lg/mL
at pH1 and 3.4 lg/mL at pH 7.4; data on ﬁle). Because of
these properties, selumetinib was classiﬁed as a tentative
class IV compound (characterized by low permeability and
low solubility).
For more convenient drug administration, and to achieve
higher exposures, a capsule formulation of selumetinib as
the hydrogen sulfate salt (AZD6244 Hyd-Sulfate) was
developed, which was used in the present study [15]. The
capsule formulation dissociates readily into sulfuric acid
and selumetinib free base at equilibrium in water (data on
ﬁle), with the capsule solubility measurements reﬂecting
those of the free base suspension (274 lg/mL at pH1, and
3.4 lg/mL pH 7.4). The selumetinib capsule has two pKa
values (acid/base ionization constants) at 2.7 and 8.2.
Excretion of selumetinib is predominantly via the feces.
The majority of selumetinib metabolites were detected as
glucuronide conjugates indicating that direct conjugation is
a signiﬁcant route of elimination for selumetinib. Selu-
metinib is metabolized by cytochrome P450 (CYPs) 1A2,
2C19, and 3A4, with CYP1A2 being responsible for the
formation of the active metabolite, N-desmethyl-selumeti-
nib, which in vitro showed 3- to 5-fold greater potency for
MEK1 inhibition than selumetinib itself. Another metab-
olite, selumetinib amide, is up to 50-fold less active than
selumetinib and therefore unlikely to contribute signiﬁ-
cantly to biological activity.
Phase I studies with selumetinib free base suspension
and capsule formulation showed that the pharmacokinetics
(PK) was approximately dose proportional across the
studied dose ranges for both formulations [15]. The max-
imal tolerated dose (MTD) for the free base suspension was
100 mg BD and 75 BD for capsule formulation. Single-
dose PK revealed that selumetinib was absorbed relatively
quickly at all dose levels with a median time to reach
maximum plasma concentration (tmax) of 1.5 h and a ter-
minal elimination half-life (t1/2) of 5–8 h. Total body
clearance of drug from plasma after an oral dose (CL/F,
ranging from 12 to 23 L/h) and volume of distribution at
steady state (Vss/F, ranging from 87 to 126 L) also
remained largely consistent across the studied dose range.
Plasma N-desmethyl-selumetinib concentrations followed
a similar PK proﬁle, although exposure was much lower
(AUC and Cmax generally \15% of parent compound).
Based on the dose-normalized area under the plasma con-
centration–time curve from time 0 to 24 h (AUC0–24), the
estimated bioavailability of the capsule formulation was
2.5-fold higher than the free base suspension [15].
The current study was undertaken to investigate the
effect of food on PK parameters of the capsule formulation,
which was taken forward for further clinical development.
It is known that food can inﬂuence the absorption of a drug
by altering one or more of the manifold variables, ranging
from postprandial changes of the gastrointestinal tract, e.g.
delayed gastric emptying, to chemical characteristics of the
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123drug itself, like modiﬁed solubility and changed metabo-
lism [16–18]. Therefore, the present study was conducted
to determine whether selumetinib should continue to be
dosed on an empty stomach or whether it could be given
with food.
Methods
Aims
The primary objective of this study was to assess whether
food inﬂuenced the rate and extent of selumetinib absorp-
tion. Secondary objectives were to determine the PK of
both selumetinib and N-desmethyl-selumetinib in the
presence and absence of food and to assess the safety and
tolerability of selumetinib in patients with advanced solid
malignancies.
An exploratory objective was included to assess the
efﬁcacy of selumetinib as measured by objective response
rate (ORR) based on response evaluation criteria in solid
tumors (RECIST 1.0) assessment in patients with measur-
able disease.
Patient selection
Male and female patients aged 18 years and over (World
Health Organization (WHO)/Eastern Cooperative Oncol-
ogy Group (ECOG) performance status 0–2) with advanced
cancer, refractory to standard therapies or for whom no
standard therapies existed, were enrolled in two investi-
gational centers in the Netherlands and three in the United
Kingdom. Patients had to be able to eat a high-fat breakfast
within a 30-min time period. Required laboratory values
consisted of absolute neutrophil count (ANC) C1,500 per
mm
3, platelets C100,000 per mm
3, hemoglobin[9.0 g/dL,
serum bilirubin \1.5 9 upper limit of normal (ULN),
aspartate aminotransferase (AST) \2.5 9 ULN, alanine
aminotransferase (ALT) \2.5 9 ULN, and calculated
serum creatinine clearance[50 mL/min (using Cockcroft-
Gault formula or by 24-h urine collection).
Exclusion criteria included patients with refractory
nausea and vomiting, chronic gastrointestinal diseases or
signiﬁcant bowel resection that would preclude adequate
absorption; pregnant or lactating women; patients that
received any radiotherapy or chemotherapy within 21 days
prior to starting the study, or any investigational drug
within the previous 28 days; patients with mean QTc
(using Fridericia’s correction) [450 ms at screening or
with factors that increased the risk of QT prolongation or
arrhythmic events or patients using concomitant medica-
tion known to prolong QT interval; and patients with brain
metastases or spinal cord suppression unless treated and
stable for at least 1 month.
Informed written consent was obtained from all patients
in accordance with federal and national guidelines, and the
study was conducted in compliance with GCP guidelines
and the Declaration of Helsinki. An additional informed
written consent was needed for optional genetic blood
sampling.
Study design
This was a Phase I, multi-center, open-label, randomized
crossover study (NCT00710515). The dose of selumetinib
was selected based upon the PK, safety, and tolerability
data from the Phase I clinical study of the Hyd-Sulfate
capsule formulation [15]. Eligible patients were random-
ized to one of two sequences. The ﬁrst sequence received a
single dose of 75 mg selumetinib with food on Day 1,
followed by a single dose of 75 mg selumetinib in the
fasted state on Day 8. The second sequence received 75 mg
selumetinib in the fasted state (Day 1) and then 75 mg
selumetinib with food (Day 8) following a 7-day wash out
period. Both groups continued on twice daily 75 mg selu-
metinib from Day 10 onwards (extension period). Patients
could continue to receive selumetinib until disease pro-
gression, unacceptable toxicity, or for as long as they
continued to derive beneﬁt from treatment. Selumetinib
capsules were taken with approximately 240 mL of water.
On Days 1 and 8, water could be taken freely up to 1 h
prior to, and from 1 h after, dosing. In the fasted state,
patients received no food or drink other than water for 10 h
prior to dosing. In the fed state, patients were fed an FDA
high-fat breakfast [19]. Patients were required to com-
pletely ingest this breakfast within 30 min and were dosed
with a single oral 75 mg dose of selumetinib 30 min after
starting to eat breakfast. A standard meal was given at 4 h
post-dose on both days, and until that time no food or drink
(other than water) was received. For the BD dosing from
Day 10 onwards, the extension period, the doses were
taken 12 h apart. Both doses were taken in the fasted state.
Breakfast could be taken from 1 h following dosing.
Evening doses were not to be taken in the 1 h preceding a
meal or in the 2 h after having ﬁnished a meal.
Treatment with selumetinib during the BD treatment
phase was withheld if patients experienced an intolerable
Adverse Event (AE) or any AEs CCommon Terminology
Criteria (CTC) Grade 3. Selumetinib treatment could be
restarted after the toxicity improved to a level considered by
theInvestigatortobemanageable(i.e.,CTCGrade1,except
fordermatologicalAEswhereCTCGrade2wasacceptable).
Treatment could be resumed at the original dose or at a
permanently reduced dose (50 mg selumetinib BD).
Cancer Chemother Pharmacol (2011) 68:1619–1628 1621
123Plasma sampling and assay methods
Blood samples were collected on Days 1 and 8, at pre-dose
(within 30 min of dosing), 15 and 30 min and 1, 1.5, 2, 4,
8, 12, 24, 36, and 48 h post-dose for analysis of plasma
selumetinib and N-desmethyl-selumetinib metabolite con-
centrations. For the analysis of selumetinib and N-desm-
ethyl selumetinib in human plasma, solid phase extraction
(SPE) was followed by high performance liquid chroma-
tography (HPLC) with tandem mass spectrometric detec-
tion (MS/MS) with a calibration range that extended from 2
to 2,000 ng/mL for selumetinib and 2–500 ng/mL for
N-desmethyl selumetinib.
13C6-selumetinib and
13C6-N-
desmethyl selumetinib were used as internal standards in
the assay. The analytes and internal standards were
extracted from human plasma by SPE using Phenomenex
Strata-X plates Polymeric Reversed Phase 96-well plates
and injected onto a ultra performance liquid chromato-
graphy (UPLC) column (Acquity(tm) UPLC
 BEH Phenyl,
1.7 m, 2.1 9 50 mm) or an HPLC column (Phenomenex
Synergi, 4 l Polar-RP, 2.0 9 50 mm). The chromato-
graphic separation and detection was achieved by liquid
chromatography and tandem mass spectrometry (LC–MS/
MS) using a Sciex API5000, respectively. Selumetinib and
N-desmethyl selumetinib concentrations were determined
by reference to calibration curves created by adding known
concentrations of selumetinib and N-desmethyl selumetinib
to control human plasma.
Pharmacokinetic analysis
Actual sample times were used for the PK analysis. All PK
computations were performed at the Department of Clini-
cal Pharmacology, Quintiles Overland Park, using Win-
Nonlin Professional 5.2 and SAS
 Version 8.2. To evaluate
the PK characteristics of selumetinib and N-desmethyl-
selumetinib in the presence and absence of food, the fol-
lowing parameters were determined by non-compartmental
analysis: (1) For selumetinib: Cmax,t max, AUC, area under
the plasma concentration–time curve from zero to the time
of the last quantiﬁable plasma concentration (AUC0–t),
terminal rate constant (kz), t1/2, volume of distribution
(apparent) during terminal (kz) phase (Vz/F) and CL/F.
Though not a true indicator of rate, tmax was used as an
indicator of the effect of food on the rate of absorption of
selumetinib. (2) For N-desmethyl selumetinib: Cmax,t max,
AUC, AUC0–t, kz, and t1/2.
Assessments
AEs were evaluated throughout the study and graded
accordingtotheCommonTerminologyCriteriaforAdverse
Events (CTCAE), version 3.0. In addition, the following
safety assessments were performed: ophthalmological
examination, ECGs, MUGA scan or echocardiogram, and
safety laboratory evaluations. Tumor assessments, per-
formedasexploratoryanalysis,weredoneevery6–8 weeks,
andResponseEvaluationCriteria inSolidTumors(RECIST
1.0) was used to assess response to treatment.
Statistical evaluation
At least 24 patients were to be randomized to the two
sequences to assess whether the 90% conﬁdence interval
(CI) for the ratio of the food effect on AUC and Cmax lie
entirely within the range of (0.8, 1.25). AUC and Cmax
were log transformed and analyzed using an analysis of
variance model allowing for the effect of food (fed or
fasted), period, sequence, and patient within sequence. The
adjusted geometric means (gls means) were estimated for
each treatment arm (fed or fasted). An estimate of the food
effect (ratio of the gls means of selumetinib in fed state:
fasted state) was calculated together with its 90% CI. A
formal test of carry-over was not performed. The potential
for any carry-over was assessed by examination of pre-dose
plasma concentrations on Day 8. An analysis of selumeti-
nib tmax data was performed on untransformed data using a
non-parametric analysis. The food effect, as measured by
patient differences in tmax (fed minus fasted states), was
analyzed using a Wilcoxon signed rank test. The Hodges–
Lehmann estimator of median food effect was calculated
and corresponding 90% CIs constructed.
The study included 3 main analysis populations: (1) the
perprotocol(PP)analysisset,(2)theSafetyanalysisset,and
(3) the evaluable for PK analysis set. The PP analysis was to
include all patients who were evaluable for PK analysis, had
complied with the protocol requirements, and had no pro-
tocol violations. The Safety analysis set was to include all
randomized patients who received at least 1 dose of study
medication. Finally, the evaluable for PK analysis set was to
includeallrandomizedpatientswhohadcompletedatleast1
period of the study and had sufﬁcient PK data available to
evaluate the primary outcome variables AUC and Cmax. The
analysis of primary PK outcome variables was presented for
both the group ‘‘evaluable for PK’’ and the group ‘‘per
protocol (PP) analysis set’’. The PP analysis was considered
primary for interpretation of data, with supportive inter-
pretation from evaluable for PK analysis.
Results
Analysis sets and protocol deviations
Of 31 randomized patients, 30 were included into the PK
and safety analysis set. One patient was excluded from the
1622 Cancer Chemother Pharmacol (2011) 68:1619–1628
123safety and PK set as she did not receive treatment. Nine
patients were excluded from the PP analysis set due to
protocol deviations. The following protocol deviations
were observed: four patients had the drug administered
more than 30 min after the breakfast; two patients did not
complete both the fed and fasted periods of the crossover
study; and ﬁve patients had insufﬁcient breakfast con-
sumption prior to dosing in the fed period.
Patient characteristics
Patient demographics and baseline disease characteristics
are shown in Table 1. The most commonly reported sites of
primary tumor were skin/soft tissue tumors [melanoma (8
patients)], and colorectal (3 patients). Overall, metastatic
disease was more commonly reported than locally
advanced tumors with the majority of metastatic disease
occurring at the following sites: lymph nodes, hepatic
(including gall bladder), and respiratory. The largest
proportion of patients (36.7%) had received two prior
chemotherapy regimens. This population was representa-
tive of typical Phase I population with pretreated patients.
Pharmacokinetics and bioavailability
Measurable concentrations of selumetinib were observed in
both fed and fasted periods during the complete sampling
period; up to 48 h (Fig. 1a). Administration of selumetinib
on an empty stomach resulted in signiﬁcantly higher
selumetinib exposure: geometric least-squares means Cmax
and AUC were reduced by 62% (ratio 0.38 90% CI 0.29,
0.50) and 19% (ratio 0.81 90% CI 0.74, 0.88), respectively,
under fed conditions, compared with exposure following
75 mg of selumetinib taken fasted (Table 2; Fig. 2). The
median tmax of selumetinib (75 mg) was delayed by
approximately 2.5 h (90% CI 1.77, 3.03) in the presence of
food. Results from a further tmax, AUC and Cmax analysis
conducted on data from all patients where PK data were
Table 1 Demographic characteristics
Demographic characteristic Fed/fasted (N = 15) Fasted/fed (N = 15) Total (N = 30)
Gender Male 9 (60) 12 (80) 21 (70)
(n and % of patients) Female 6 (40) 3 (20) 9 (30)
Age (years) Mean (SD) 59.7 (9.01) 56.6 (10.25) 58.1 (9.61)
Range 44/77 32/70 32/77
Age group (years) C18 to B65 12 (80.0) 13 (86.7) 25 (83.3)
(n and % of patients) [65 3 (20) 2 (13.3) 5 (16.7)
WHO performance status 0 6 (40.0) 7 (46.7) 13 (43.3)
(n and % of patients) 1 2 (13.3) 7 (46.6) 9 (30.0)
2 6 (40.0) 0 6 (20.0)
3–4 0 0 0
Tumor site Skin/soft tissue 3 5 8 (26.7)
(n and % of patients) Colon/colorectal/rectal 3 3 6 (20)
Head & Neck 1 1 2 (6.7)
Esophagus 1 1 2 (6.7)
Biliary tract 2 0 2 (6.7)
Liver 1 1 2 (6.7)
Renal 2 0 2 (6.7)
Bladder 1 1 2 (6.7)
Other 1 3 4 (13.3)
Number of prior regimens 0 2 (13.3) 3 (20.0) 5 (16.7)
(n and % of patients) 1 5 (33.3) 2 (13.3) 7 (23.3)
2 5 (33.3) 6 (40.0) 11 (36.7)
[2 3 (20.0) 4 (26.7) 7 (23.3)
Race Caucasian 12 (80) 15 (100) 27 (90)
(n and % of patients) Black 1 (6.7) 0 1 (3.3)
Asian—Non Japanese 1 (6.7) 0 1 (3.3)
Other 1 (6.7) 0 1 (3.3)
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123evaluable were very similar to those observed in the PP
population. The geometric mean clearance of selumetinib
was lower (19%) in the fasted state compared with the fed
state reﬂecting the observed difference in AUC. The small
difference in the volume of distribution (Vz/F) observed
between the fasted and fed states did not translate into an
appreciable difference in half-life (Table 2). Similar results
were observed in the PK population.
Measurable concentrations of N-desmethyl-selumetinib
were observed in both the fed and fasted periods for up to
24 h (Fig. 1b). Similar to selumetinib, the mean concen-
trations of N-desmethyl-selumetinib in the fed state were
lower in comparison to the fasted state, and the tmax for
N-desmethyl-selumetinib was delayed when selumetinib
was administered in the presence of food. A decrease of
approximately 55% in the geometric mean Cmax and 9% in
the geometric mean AUC of N-desmethyl-selumetinib was
observed when selumetinib was given in the presence of
food compared with the fasted state (Table 2). Whilst the
presence of food reduced the exposure to selumetinib
compared with the fasted state, the ratio of N-desmethyl-
selumetinib to selumetinib (metabolite to parent) remained
similar (0.06 and 0.07 ng*h/mL for fed and fasted state,
respectively). Hence, both the median plasma
concentration of the parent compound and of the
N-desmethyl-metabolite were decreased in a similar extent
when selumetinib was given in the presence of food. The
median tmax for N-desmethyl-selumetinib was delayed by
approximately 3 h in the fed condition, also comparable to
the delayed tmax of selumetinib.
Safety and tolerability
Of the 31 randomized patients, 28 completed the food
effect period that involved 2 single doses of selumetinib
(on Day 1 and Day 8) and continued on BD dosing from
Day 10 for a mean duration of 58.7 days (median
52.0 days; range, 7–229 days). Two patients did not enter
the extension period following voluntary discontinuation
from the study. In the extension part, 10 patients had one or
more dose reductions largely due to AEs (n = 6).
Adverse events
The most frequently reported AEs overall (regardless of
severity, causality, or seriousness) were nausea, rash,
diarrhea, fatigue, constipation, dyspnoea, and vomiting
(Table 3). Eighteen out of 30 (60.0%) patients (overall
safety population) reported an AE of grade 3 or higher
during the study, but only 4 (13.3%) of whom had grade 3
AEs (Table 4) that were assessed as potentially treatment
related. The 2 (6.7%) grade 4 AEs were not considered to
be causally related to study treatment (one patient experi-
enced worsening of dyspnoea and one patient had hyper-
calcaemia). Serious AEs and AEs leading to
discontinuation were reported by 40 and 20% of patients,
respectively. One patient (3.3%) died whilst on study as a
result of an intestinal perforation due to disease progres-
sion. Although the case was reported as an AE leading to
death, it was in fact due to disease progression. AEs that
were only reported following chronic exposure to selu-
metinib in the extension phase were peripheral edema,
hypertension, dry mouth, vision blurred, skin ﬁssures, joint
swelling, acne (acne/dermatitis acneiform), and dyspepsia.
The most common AEs reported following single exposure
to selumetinib were diarrhea, nausea, and abdominal pain.
Laboratory and vital sign ﬁndings in this study were
generally consistent with those seen previously in selu-
metinib monotherapy studies. No notable changes in vital
signs were observed.
Anti-tumor activity/efﬁcacy
Although response evaluation was not the primary end
point of this study, 28 patients were evaluable for objective
response by RECIST. Two partial responses (7.1%) were
observed (Day 71 and on Day 189). Both patients had
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123cutaneous melanoma and were still alive and continuing
study treatment at data cut-off. In addition, 5 (18%)
patients had the best overall response of stable disease, 2
for [100 days (1 colorectal cancer and 1 melanoma
patient), 2 patients for [50 days (1 liver cancer and 1
prostate cancer).
Discussion
In this Phase I, multi-center, open-label, randomized
crossover study, the inﬂuence of food on the rate and extent
of selumetinib oral capsule absorption in male and female
patients with solid malignancies was determined. In addi-
tion to selumetinib, concentrations of its 3- to 5-fold more
active metabolite, N-desmethyl-selumetinib, were also
determined [15], as any changes in the metabolite concen-
trations may inﬂuence the treatment efﬁcacy. The present
study showed that the extent (Cmax and AUC) and rate of
absorption of selumetinib was signiﬁcantly reduced in the
presence of food. It is therefore recommended that for
future clinical studies, selumetinib should continue to be
administered on an empty stomach (no food or drink other
than water for 2 h prior to dosing and 1 h after dosing).
Table 2 Inﬂuence of food on the rate and extent of selumetinib absorption (A) and pharmacokinetic parameters for (B) selumetinib and
(C) N-desmethyl-selumetinib in fed and fasted state [all PP population]
Selumetinib PK parameters Treatment n Geometric LS mean Pairwise comparision
Ratio of fed/fasted 90% CI
(A)
AUC (ng*h/mL) Fed 21 4664
Fasted 19 5782 0.81 0.74, 0.88
AUC0–t (ng*h/mL) Fed 21 4504
Fasted 21 5639 0.80 0.73, 0.88
Cmax (ng/mL) Fed 21 557
Fasted 21 1450 0.38 0.29, 0.50
Selumetinib PK parameters Treatment n Geometric mean CV (%)
(B)
tmax (h) Fed 21 4.0
a 1.0, 11.6
a
Fasted 21 1.08
a 0.5, 4.0
a
t1/2 (h) Fed 21 8.6 44.5
Fasted 19 9.4 33.0
CL/F (L/h) Fed 21 16.0 35.8
Fasted 19 12.9 29.9
Vz/F(L) Fed 21 199.4 56.2
Fasted 19 175.2 46.8
N-desmethyl-selumetinib PK parameters Treatment n Geometric mean CV (%)
(C)
Cmax (ng/mL) Fed 21 33.5 63.8
Fasted 21 73.9 45.7
tmax (h)
a Fed 21 4.0
a 1.0, 11.6
a
Fasted 21 1.50
a 0.5, 4.0
a
AUC (ng*h/mL) Fed 13 379.1 49.0
Fasted 15 418.4 36.5
AUC0–t (ng*/h/mL) Fed 21 282.4 68.2
Fasted 21 376.4 41.0
t1/2 (h) Fed 13 6.8 56.6
Fasted 15 7.7 45.5
a Data are presented as median (min, max)
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123The exact mechanism for decreased selumetinib expo-
sure in the presence of a high-fat meal is unknown and may
be a result of saturation of drug dissolution in the intestinal
ﬂuids with an increased pH. In the average person, the
basal gastric secretion in the fasted stomach is estimated to
be 300 mL and in the fasted small intestine about 500 mL,
and both can increase up to 5-fold after a high-fat meal [16,
18, 20]. On the other hand, fatty foods also stimulate bile
secretion that can cause a signiﬁcant rise in the pH of the
proximal small bowel, the major site for selumetinib
absorption [16, 21]. The presence of more ﬂuid in the
gastrointestinal tract may actually improve the dissolution
rate and can result in increased solubility due to increased
wetting of the drug and increased micellar solubilization
[16, 22]. However, since the food effect consisted of a
decrease in selumetinib exposure, the effect of the raised
pH in the proximal bowel might be of greater importance
and help explain the observed decrease in absorption of
selumetinib. Additionally, the selumetinib capsule has a
hydroxypropylmethylcellulose coating and will tend to
disintegrate slowly thus preventing early activation by
gastric acid and probably resulting in a controlled release.
Delayed gastric emptying is believed to be the major
mechanism for delayed absorption and could be the
underlying mechanism for the delayed tmax of selumetinib
given in the presence of food. The presence of food in the
stomach can decrease the rate of presentation of the drug to
the small intestine and delay the onset of absorption,
especially for rapidly absorbed drugs (Cmax achieved
within 2 h in fasted state). For selumetinib in fasted state,
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Fig. 2 AUC a and Cmax b of selumetinib in fed and fasted state (PP
population)
Table 3 Most frequent AEs (C10% of patients) in safety population
Number (%) of patients
Total (N = 30)
Nausea 18 (60.0)
Rash 16 (53.3)
Diarrhea 14 (46.7)
Fatigue 13 (43.3)
Constipation 11 (36.7)
Dyspnoea 10 (33.3)
Vomiting 9 (30.0)
Abdominal pain 8 (26.7)
Dizziness 8 (26.7)
Edema peripheral 7 (23.3)
Anemia 7 (23.3)
Headache 7 (23.3)
A patient can have one or more preferred term (PT) reported under a
given system organ class
Patients with multiple events in the same PT are counted only once
for that PT, within each period
Adverse events with an onset date during the 30 day follow-up are
assigned to the period in which their last dose was administered
Table 4 SAE of CCTC grade 3 reported in C2 patients (safety
population)
Number (%) of patients
Total (N = 11)
Dyspnoea 3 (10.0)
Abdominal pain 2 (6.7)
Constipation 2 (6.7)
Vomiting 2 (6.7)
Anemia 2 (6.7)
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123Cmax was determined in a previous study at 1.5 h and
therefore could ﬁt in this category of drugs [15].
The study population was representative of the broader
Phase I clinical population of patients with advanced solid
malignancies in terms of baseline and demographic char-
acteristics. As observed in previous selumetinib mono-
therapy studies [14, 15, 19], the exploratory efﬁcacy
analysis of this study suggests that selumetinib is biologi-
cally active. During the study, two patients with melanoma
had partial responses and four patients had stable disease;
two patients had stable disease for [100 days (1 patient
with colorectal cancer and 1 patient with skin/soft tissue
cancer) and two patients had stable disease for[50 days (1
patient with prostate cancer and 1 patient with liver can-
cer). However, it should be noted that this study was not
designed to investigate the efﬁcacy of selumetinib, and
tumor mutation status (e.g. BRAF V600E or KRAS) was
not determined. Limited responses were to be expected
from this advanced patient population who had progressed
on multiple prior anti-cancer treatments, consistent with
that seen in the Phase I trials.
The AE proﬁle in this study was similar to that seen in
previous selumetinib monotherapy studies [14, 15, 19]. The
most common AEs included gastrointestinal AEs, derma-
tological AEs, and fatigue. The majority of these events
occurred during BD dosing.
Food effect data are available with other MEK inhibitors
that have been used clinically including CI-1040 (PD-
184352) and PD-0325901. CI-1040 was the ﬁrst MEK
inhibitor to enter the clinic, and in the Phase I study, dosing
was initially performed in the morning on an empty
stomach (after an overnight fast) [23]. It has been proposed
that low aqueous solubility is responsible for the poor oral
absorption of CI-1040 [23–25]; solubility of\1 lg/mL in
pH 6.5 phosphate buffer. Administration of CI-1040 at 800
and 1,600 mg with a high-fat meal resulted in a 4.5-fold
increase in drug exposure of CI-1040 and a 5-fold increase
of the metabolite PD-0184264. The MTD and recom-
mended Phase II dose (RP2D) was determined at 800 mg
BID administered with food. The mechanism postulated for
the observed increase in CI-1040 exposure in the presence
of food was facilitated dissolution either by the fat in the
food or because of increased presence of bile salts. This
would be in line with preclinical dissolution data in which
the addition of detergents to the dissolution media
increased dissolution. Development of CI-1040 was dis-
continued in Phase II due to lack of efﬁcacy. PD-0325901,
another non-ATP competitive MEK inhibitor [26], is a
derivative of CI-1040 with improved aqueous solubility of
190 lg/mL in pH 6.5 phosphate buffer and is, like selu-
metinib, referred to as a second generation MEK inhibitor.
PD-0325901 had a 50-fold higher potency than CI-1040,
improved bioavailability, increased metabolic stability, and
increased duration of target suppression (inhibition of ERK
phosphorylation). In fasted conditions, PD-0325901 was
absorbed rapidly with a tmax of 1 h, and Cmax and AUC
showed proportional increase at the tested doses; however,
the effect of food on pharmacokinetics was not reported in
the Phase I study. We would expect the food effect to be
less than that for CI-1040 because of the improved solu-
bility of PD-0325901. Due to lack of response and
observed toxicity, development of PD-0325901 in Phase II
was discontinued [27].
CH497655 (RO4987655) is a new MEK inhibitor and is
currently being evaluated in a Phase I trial. Although a
study has been performed in healthy volunteers, no infor-
mation has been provided about the effect of food on the
absorption. PK in healthy volunteers with doses up to 4 mg
showed rapid absorption (median tmax of 1 h) and low
variability [28].
In conclusion, PK parameters of orally administered
drugs may be signiﬁcantly altered in the presence of food
due to changes in solubility, absorption and metabolism.
The current study demonstrated that intake of a high-fat
meal decreases the extent and rate of selumetinib absorp-
tion and suggests that a 75 mg dose of selumetinib capsule
formulation given twice a day has an acceptable safety
proﬁle in this advanced cancer population. It is recom-
mended that for further clinical studies, selumetinib should
be taken on an empty stomach.
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